Observational studyScientific reports2025
Serum osteocalcin is associated with the presence of hepatic steatosis in Chinese patients with chronic hepatitis B.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to explore the potential association between serum osteocalcin (OCN) and hepatic steatosis (HS) in patients with chronic hepatitis B (CHB). In this cross-sectional study, a total of 263 CHB patients were enrolled and their baseline profiles were analyzed from January 2020 to January 2022. HS was defined based on the controlled attenuation parameter (CAP) value. Specifically, patients with a CAP value exceeding 248 dB/m were diagnosed with HS. Among the 263 patients, 76 with HS and 187 without HS. The levels of serum OCN were lower in with HS than in without HS participants (P = 0.002). Scatter plots with Pearson correlation coefficients indicated that there was a negative correlation among OCN levels with CAP (r = - 0.134, P = 0.030), ALB (r = - 0.21, P < 0.001), and GLB (r = - 0.139, P = 0.025). Logistic regression analysis showed that the OCN levels (OR, 0.92; P = 0.005) were negatively associated with HS, and age (OR, 1.04; P = 0.012), GLB(OR, 0.93; P = 0.039), ALT (OR, 1.05; P = 0.002), and γ-GT (OR,1.04; P = 0.001) positively associated with HS. In stratified analysis, the association remained significant in the age (P = 0.020), OCN (P = 0.026), GLB (P = 0.037), ALT (P = 0.020), and γ-GT (P < 0.001) in CHB patients. Our finding suggested that serum OCN was independently and negatively associated with HS in CHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.